20-year experience on prenatal diagnosis in a reference university medical genetics center in Turkey

Burak DURMAZ1, Hilmi BOLAT1, Zehra CENGİLİZ1, Fuat AKERCAN2, Tuba SÖZEN TÜRK2, Erhan PARILTAY3, Aslı Ece SOLMAZ1, Mert KAZANDI4, Emin KARACA1, Asude DURMAZ1, Ayça AYKUT1

1Department of Medical Genetics, Faculty of Medicine, Ege University, Izmir, Turkey
2Division of Perinatology, Department of Obstetrics and Gynecology, Faculty of Medicine, Ege University, Izmir, Turkey
3Division of Genetics, Department of Pediatrics, Faculty of Medicine, Ege University, Izmir, Turkey

Introduction

Prenatal screening and diagnostic testing for chromosomal abnormalities have expanded dramatically over the past two decades [1]. After reviewing 68,159 live born baby surveys from 1969 to 1982, 1 in 156 live births were found to be carrying a major chromosomal abnormality [2]. The implementation of effective screening tests decreased the need for invasive diagnostic testing such as amniocentesis (AC), chorionic-villus sampling (CVS) or cordocentesis; thus, reducing the risk of procedure-related miscarriages for a healthy pregnancy. Screening tests, however, have limitations which include both false positive and false negative results and currently cannot detect all chromosomal anomalies.

While more advanced procedures such as cell-free fetal DNA (cffDNA) testing from maternal blood are available, invasive prenatal tests are still being used extensively for prenatal diagnosis in most countries. Amniocentesis and CVS are considered safe and accurate procedures. The risk of major complication associated with midtrimester amniocentesis at 15–16 weeks of gestation is 1 in 1600. The risk of inducing miscarriage is only approximately 1%–2% over the baseline risk for any pregnancy at this stage of gestation [3]. The decision regarding screening to mitigate the risk of having a child with chromosomal abnormality prior to the child's birth is very personal and deeply complex. The presence of a family history of aneuploidy or genetic disorders, obstetrical and medical history, demographic...
information, attitudes and religious beliefs, education levels and economic concerns are all influencing factors [4]. Investigation of these factors may offer invaluable insights that will be used in genetic counseling services prior to prenatal diagnosis, and also in the development of more effective decision-making strategies. Therefore, the aim of this study was to evaluate and to discuss the demographic data, indications and cytogenetic results of 9297 cases that opted for prenatal sampling procedures.

2. Materials and methods
The study was conducted retrospectively using the records of AC, CVS, and cordocentesis referrals for the last 20 years in a University Medical Genetics Center. A total of 9297 women between 18–54 years old were included in the study. Invasive prenatal testing was performed for each case appropriate to its week of gestation (CVS at 10–13 weeks of gestation, AC at 16–22 weeks of gestation, and cordocentesis at 20–24 weeks of gestation). In all cases, genetic counseling was provided, outlining the chances of finding chromosomal abnormality in the fetus and the risks associated with invasive prenatal testing procedures. Invasive prenatal testing was performed only after written informed consent had been obtained.

We grouped the cases according to the standard indications of prenatal testing (Table 1):

1. Advanced maternal age (AMA) (≥35 years at the expected time of delivery)
2. Abnormal result of maternal serum screening tests
3. Abnormal ultrasound (USG) findings
4. Referral for molecular analysis
5. Chromosome abnormality in previous pregnancy
6. Advanced maternal age with abnormal ultrasound findings
7. Parental anxiety
8. Abnormal parental karyotype
9. Chromosome abnormality in previous pregnancy with advanced maternal age
10. Recurrent pregnancy loss
11. Other indications

Cases with both AMA and abnormal USG finding, or AMA and chromosome abnormality in previous pregnancy were grouped separately.

Cases were further classified into groups according to age:
1. 21–25 years
2. 26–30 years
3. 31–35 years
4. 36–40 years
5. 41–45 years
6. 46–54 years

Table 1. Number of chromosomal abnormalities detected in regard to the indications of prenatal diagnosis.

| Indications                                         | Number of total cases (%) | Number of abnormal karyotype with inv(9) (%) | Number of abnormal karyotype without inv(9) (%) | Positive predictive value (%) |
|-----------------------------------------------------|---------------------------|---------------------------------------------|-------------------------------------------------|-------------------------------|
| Advanced maternal age                               | 4482 (48.2)               | 205 (4.5)                                   | 160 (3.5)                                       | 3.5                           |
| Increased risk in MSS tests                         | 2387 (25.7)               | 107 (4.4)                                   | 69 (2.8)                                        | 2.8                           |
| Abnormal ultrasound findings                        | 1021 (11)                 | 121 (11)                                    | 101 (9.8)                                       | 9.8                           |
| Referral for molecular analysis                     | 695 (7.5)                 | 14 (2)                                      | 5 (0.7)                                         | 0.7                           |
| Previous pregnancy with chromosome abnormality     | 249 (2.7)                 | 19 (7.8)                                    | 18 (7.2)                                        | 7.2                           |
| Other indications*                                  | 172 (1.8)                 | 6 (3.4)                                     | 4 (2.3)                                         | 2.3                           |
| Advanced maternal age with abnormal ultrasound findings | 106 (1.1)               | 30 (28)                                     | 29 (27.3)                                       | 27.3                          |
| Maternal anxiety                                    | 86 (0.9)                  | 5 (5.8)                                     | 4 (4.6)                                         | 4.6                           |
| Parental abnormal karyotype                         | 41 (0.4)                  | 15 (36.5)                                   | 15 (36.5)                                       | 36.5                          |
| Increased risk in MSS tests with abnormal ultrasound findings | 26 (0.3)                 | 4 (15.3)                                    | 4 (15.3)                                        | 15.3                          |
| Recurrent pregnancy loss                            | 21 (0.2)                  | 3 (14.2)                                    | 3 (14.2)                                        | 14.2                          |
| Previous pregnancy with chromosome abnormality and advanced maternal age | 11 (0.1)                 | 9 (81.8)                                    | 9 (81.8)                                        | 81.8                          |
| Total                                               | 9297 (100)                | 538                                         | 421                                             | -                             |

MSS: maternal serum screening, inv: inversion, *stillbirth in previous pregnancy, failure in previous prenatal test
A positive cytogenetic result was accepted if the obtained karyotype was other than 46,XX or 46,XY and these results were grouped as numerical or structural abnormality. The study was approved by Ege University Scientific Research Ethics Committee with the approval number 17-8.1/11.

2.1. Statistical analyses
The total number of events and the percentages of each group were recorded. Chi-square and logistic regression analysis were performed in order to give the statistical likelihood of different events. A p-value of < 0.05 was considered statistically significant. Positive predictive values were calculated for each of the prenatal indications with the cytogenetic results. The Shapiro–Wilk test was employed to verify the normality of the data. The data generated from the study were compared and analyzed using SPSS v: 19.0 software (IBM Corp., Armonk, NY, USA) with confidence interval set at 95%.

3. Results
Analyses were carried out on 9297 prenatal sample results; AC (8363 cases), CVS (626 cases), and cordocentesis (308 cases). The Shapiro–Wilk test revealed normal distribution of the data (p > 0.05). Our culture success rate was 98.4%. The rate of chromosomal abnormalities was found to be 4.5% excluding inversion 9 (inv(9)) polymorphism being trisomy 21 was the most common cytogenetic abnormality. Mean age for all pregnancies was 33.17±5.9; ranging between 18–54 years, whereas 50.8% of cases were advanced maternal age (≥35 years of age). The mean gestational duration of the pregnancies at the time of testing was 17.4±2.2 weeks. It is interesting to note that the number of referrals decreased significantly after 2009.

By volume, the indications for prenatal diagnosis were AMA in 4482 cases (48.2%), abnormal maternal screening tests in 2387 cases (25.7%), abnormal USG findings in 1021 cases (11.1%), referral for molecular analysis in 695 cases (7.5%), and chromosome abnormality of a previous pregnancy in 249 cases (2.7%). Further indications included AMA with abnormal ultrasound finding in 106 cases (1.1%), parental anxiety in 86 cases (0.9%), having abnormal parental karyotype in 41 cases (0.4%), recurrent pregnancy loss in 21 cases (0.2%), abnormality in previous pregnancy with AMA in 11 cases (0.1%), other indications including stillbirth in previous pregnancy, failure in previous prenatal test, which accounted for 172 cases, (1.8%). Table 1 summarizes the detected chromosomal abnormalities according to the indications of prenatal diagnosis.

Of the 9297 cases, chromosome anomalies and inv(9) polymorphism were determined in 538 cases (5.8%). Numerical abnormalities accounted for 60.1% and structural abnormalities made up the remaining 39%. Of the numerical chromosomal abnormalities, trisomy 21 was noted in 167 cases (31%), an abnormality of sex chromosome in 57 cases (10.6%), trisomy 18 in 42 cases (7.8%), marker chromosome in 18 cases (3.3%), triploidy or tetraploidy in 16 cases (3%), trisomy 13 in 13 cases (2.4%), and mosaic chromosomal abnormalities were noted in 11 cases (2%). With reference to the structural anomalies, 64 cases had translocation (11.9%), in which 45 patients had reciprocal, and 19 patients had Robertsonian translocation, 19 cases of inversion (3.5%), and 10 cases of deletion (1.9%). Rare structural anomalies were reported in 4 cases in which 3 cases had derivative chromosome 1 and 1 case had isochromosome X (0.7%). Additionally, inv(9) polymorphism was found in 117 cases (21.7%). Chromosome analysis was recommended from the parents of patients having structural chromosomal anomalies. The outcomes of 154 patients, whose records have been reached, whose parents were alive and who wanted to have the karyotype analysis were evaluated. Segregation analysis revealed that, 24 reciprocal translocations, 12 Robertsonian translocations, 13 inversions, 3 derivative chromosomes, 1 deletion, and 87 inv(9) polymorphisms were segregated from either parent and noted as familial. On the other hand, 5 reciprocal translocations, 2 Robertsonian translocations, 6 deletions, and 1 isochromosome were de novo. Table 2 summarizes the distribution of numerical and structural abnormalities.

Table 2. Distribution of numerical and structural chromosomal abnormalities.

| Chromosomal abnormalities | Number (%) |
|---------------------------|------------|
| Numerical                 | 324 (60.1) |
| Trisomy 21                | 167 (31.0%)|
| Sex chromosome abnormality| 57 (10.6%) |
| Trisomy 18                | 42 (7.8%)  |
| Marker chromosome         | 18 (3.3%)  |
| Triploidy/tetraploidy     | 16 (3.0%)  |
| Trisomy 13                | 13 (2.4%)  |
| Mosaic chromosomal abnormality | 11 (2%) |
| Structural                | 214 (39.0%)|
| Translocation             | 64 (11.9%) |
| Inversion                 | 19 (3.5%)  |
| Deletion                  | 10 (1.9%)  |
| Rare chromosomal abnormality* | 4 (0.7%)  |
| Inv(9) polymorphism       | 117 (21%)  |
| Total                     | 538 (100%) |

*Rare chromosomal abnormality (derivative chromosome abnormality and isochromosome) (Inv: inversion, n: number).
chromosomal anomalies.

The indication of “chromosome abnormality in previous pregnancy with advanced maternal age” was found to be the most strongly associated with chromosomal abnormalities (81.8%). A positive predictive value (PPV) was also detected in other indications such as parental abnormal karyotype (36.5%), advanced maternal age with abnormal ultrasound findings (27.3%), increased risk in MSS tests with abnormal ultrasound findings (15.3%), recurrent pregnancy loss (14.2%), abnormal ultrasound findings (9.8%), previous pregnancy with chromosomal abnormality (7.2%), maternal anxiety (4.6%), AMA (3.5%), increased risk in MSS tests (2.8%), and others (2.3%). The indication “referral for molecular analysis” produced a PPV of only 0.7% (Table 1).

Logistic regression analysis revealed a strong correlation with the risk of having trisomy 21 and AMA (2.6%, p 0.001). However, while the risk increased for AMA pregnancies in terms of trisomy 18 and 13, the difference was not statistically significant in Chi-square test (p > 0.05). The risk of having a trisomy 21 pregnancy was then evaluated across different age groups with logistic regression analysis. When the 21–25 age group was compared to the older age groups, risk doubled in the 36–40 age group. This was 5 times and 10 times higher in the 41–45 and 46–50 age groups, respectively. Table 3 summarizes the risk of having a child with Down Syndrome according to the different age groups.

A total of 2387 cases were referred due to increased risk in maternal serum screening. We were able to access the detailed data of 1747 cases. In 1497 cases, the risk was below 1/250 (high risk), and in 250 cases, the risk was 1/250 or higher (low risk). We were able to establish a cut-off value of 1/250 for trisomy 21. However, Chi-square test was unable to establish any significant correlation between maternal serum screening test results higher than 1/250 and trisomy 21 occurrence (p > 0.05). All the pregnancies that were found to have trisomy 21 also had an increased risk in maternal serum screening which is below 1/250 cut-off value.

**4. Discussion**

Genetic counseling is an essential step prior to prenatal testing and plays a very important role in meeting the expectations of families about prenatal screening tests. Understanding the risks and the likelihood ratio of detecting chromosomal abnormalities when these procedures were applied, have become very important aspects of the pretest genetic counseling [5]. In this study, chromosomal abnormalities has been reported in 4.5% of all cases with the exception of inv(9) polymorphism which is higher than the previous reports [4,6–8]. AMA is a well-known risk factor for chromosomal abnormality [6–11].

The detection rate of abnormal karyotype in women over ≥35 years old was higher than that previously reported by Xiao et al. (2.79%) [8]. However, it is similar to the study reported by Balkan et al. (4.9%) [12].

In our study, the main indication for prenatal testing was AMA and the second indication was the presence of abnormal MSS. In recent years, particularly in developed countries, the mean age of pregnant women has increased [13]. In previous studies, while the most common indications for prenatal testing were AMA [14,15] and MSS [9], with the increased development of MSS procedures, chromosomal abnormality detection rates have increased to higher rates. This caused MSS tests to become a more frequent indication for an invasive testing [16]. In a recent retrospective study, it was shown that there was a significant change in the trend of indications for invasive prenatal diagnosis from advanced maternal age in 2009 to positive screening tests by 2014 [17]. In a study from Turkey, highest chromosomal anomaly detection rate was observed in pregnant women with increased risk in MSS (3.2%) [18]. Although the use of noninvasive maternal next generation screening tests is gradually increasing, their sensitivity and specificity should be questioned. Therefore, the meaning of the rates determined in traditional screening tests should also be well explained in genetic counseling sessions. In our study, there was no increase in the rate of chromosomal anomaly detection rate in parallel with the rate determined in MSS. However, trisomy 21 detection rate was significantly higher in women having a MSS test above 1/250 cut-off value [18]. An important aspect of prenatal care has always been the consideration of trisomy 21. In our study, the risk of having a trisomy 21 pregnancy was also evaluated across different age groups. When the 21–25 age group was compared to the older age groups, risk doubled in the 36–40 age group. This was found to be 5 and 10 times

| Age  | DS risk (X) | B    | S.E  | OR  | %95 C.I. | p     |
|------|------------|------|------|-----|---------|-------|
| 26–30| 1          | 0.143| 0.389| 1.154| 0.538–2.475 | 0.713 |
| 31–35| 1          | 0.120| 0.372| 1.127| 0.543–2.337 | 0.748 |
| 36–40| 2          | 0.806| 0.339| 2.238| 1.151–4.351 | 0.018*|
| 41–45| 5          | 1.669| 0.363| 5.305| 2.603–10.814| <0.001*|
| 46–54| 10         | 2.285| 0.684| 9.83 | 2.573–37.555| 0.001*|

The risk is given as (X) times. The dependent variable is the presence of Down Syndrome and the independent variable is the maternal age, grouped in accordance with our study population. (B: beta, S.E: standard error, OR: odds ratio, C.I.: confidence interval, *:p < 0.05).
increased in 41–45 and 46–50 age groups, respectively. However, we have not found any significant association between AMA and trisomy 13 or trisomy 18.

The indication of “Chromosome abnormality in previous pregnancy with advanced maternal age” was found to be the indication, most strongly associated with any chromosomal abnormality (81.8%). It was considered to be a high indicator of an abnormal karyotype; therefore, the cytogenetic results should be thoroughly reviewed for any subtle chromosomal abnormality. “Fetal anomalies in prenatal ultrasonography” was the most common indication in some other studies associated with chromosomal anomalies which ranged between 5.3%–20.3% [14–15,19–21]. Our PPV value for abnormal USG findings was 9.8% which was similar to previous results. Moreover, accompanying indications such as “advanced maternal age” or “abnormal MSS tests” in conjunction with abnormal USG findings increased the PPV value. Advanced maternal age with abnormal USG findings produced a rate of 27.3%, whilst abnormal MSS tests together with abnormal ultrasound findings had a rate of 15.3%. In a recent study by Sun et al. demonstrated that ultrasound soft markers were the most common prenatal diagnostic indication among 3387 patients, but the detection rate of abnormal karyotypes was only 2.02%. Additionally, it was 46.97% in the genome-wide NIPT-positive group which they concluded that NIPT should not be recommended as the first-tier screening for chromosomal aberration for pregnancies with ultrasound soft markers or pathological ultrasound findings [22].

There is an increase in the demand for prenatal tests due to lower costs and availability particularly after 2003. Amniocentesis is the most preferred prenatal procedure as, a 5-year retrospective study showed that, 86% of amniocentesis were safe and free from any complications [23]. Although the range and quality of prenatal tests have increased over the years, the number of requests for these tests in our department has declined since 2009. One possible explanation could be the decentralization of specialized services. The fact that these tests can now be carried out in more provincial hospitals may explain the decline since 2009. A cheaper, faster, and less intrusive option of USG imaging and combined screening tests together with noninvasive next generation prenatal screening may have also contributed to this decline.

Moreover, our culture success rate was 98.4%, which was around in the level of upper range in the studies reported from our country. In one of those studies, a cytogenetic result could be obtained in 98.8% of the 6124 cases evaluated by using AC [24]. In another study the culture success rate was 99% [25]. However, these studies reported only amniocentesis data. To gain a broader perspective, our study included all forms of prenatal sampling procedures.

5. Conclusion
As technology evolves, the opportunity for early diagnosis of genetic diseases has become a very useful addition to the healthcare system. We think that, by reviewing these indications and their corresponding results, it provides a helpful insight for genetic counseling prior prenatal diagnosis and also adds useful background to the strategic development of effective and long-term genetic services.

Conflict of interest
The authors declare no conflict of interest.

Acknowledgment
The study was approved by Ege University Scientific Research Ethics Committee with the approval number 17-8.1/11.

References
1. Fonda AJ, Stoll K, Bernhardt BA. Pre-and post-test genetic counseling for chromosomal and Mendelian disorders. Seminars in Perinatology 2016; 40 (1): 44-55. doi: 10.1053/j. semperi.2015.11.007
2. Benn PA. Prenatal diagnosis of chromosomal abnormalities through chorionic villus sampling and amniocentesis. In: Milunsky A, Milunsky JM (editors). Genetic Disorders and the Fetus: Diagnosis, Prevention, and Treatment. 7th ed. New Jersey, NJ, USA: JohnWiley & Sons Inc; 2004. pp. 178-267.
3. Nussbaum RL, McInnes RR, Huntington FW. Thompson & Thompson Genetics in Medicine. 8th ed. Chicago, IL, USA: Elsevier Inc; 2016.
4. Driscoll DA, Gross S. Clinical practice. Prenatal screening for aneuploidy. New England Journal of Medicine 2009; 360 (24): 2556-2562. doi: 10.1056/NEJMcp0900134
5. Levy B, Stosic M. Traditional prenatal diagnosis: past to present. Methods in Molecular Biology 2019; 1885: 3-22. doi: 10.1007/978-1-4939-8889-1_1
6. Hsu LY, Benn PA, Tannenbaum HL, Perlis TE, Carlson AD. Chromosomal polymorphisms of 1916 and Y in 4 major ethnic groups: a large prenatal study. American Journal of Medical Genetics 1987; 26 (1): 95-101. doi: 10.1002/ajmg.1320260116
7. Mozdarni H, Meybodi AM, Karimi H. Impact of pericentric inversion of Chromosome 9 [inv (9) (p11q12)] on infertility. Indian Journal of Human Genetics 2007; 13 (1): 26-29. doi: 10.4103/0971-6866.32031
8. Xiao H, Yang YL, Zhang CY, Liao EJ, Zhao HR et al. Karyotype analysis with amniotic fluid in 12365 pregnant women with indications for genetic amniocentesis and strategies of prenatal diagnosis. Journal of Obstetrics and Gynaecology 2016; 36 (3): 293-296. doi: 10.3109/01443615.2015.1041889
9. Ferguson-Smith MA, Yates JRW. Maternal age specific rates for chromosome aberrations and factors influencing them: report of a collaborative European study on 52965 amniocenteses. Prenatal Diagnosis 1984; 4: 5–44. doi: 10.1002/pd.1970040704

10. Tseng JJ, Chou MM, Lo FC, Lai HY, Chen MH et al. Detection of chromosome aberrations in the second trimester using genetic amniocentesis: experience from 1995–2004. Taiwanese Journal of Obstetrics and Gynecology 2006; 45 (1): 39–41. doi: 10.1016/S1028-4559(09)60188-1

11. Zhu Y, Lu S, Bian X, Wang H, Zhu B et al. A multicenter study of fetal chromosomal abnormalities in Chinese women of advanced maternal age. Taiwanese Journal of Obstetrics and Gynecology 2016; 55 (3): 379–384. doi: 10.1016/j.tjog.2016.01.002

12. Balkan M, Akbas H, Kalkanli S, Sakar MN, Fidanboy M et al. Evaluation of clinical and cytogenetic findings on 1068 second-trimester amniocenteses in Southeast Turkey. Clinical and Experimental Obstetrics and Gynecology 2011; 38 (4): 364–368.

13. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenatal Diagnosis 2011; 31 (1): 7–15. doi: 10.1002/pd.2637

14. Chang YW, Chang CM, Sung PL, Yang MJ, Li WH et al. An overview of a 30-year experience with amniocentesis in a single tertiary medical center in Taiwan. Taiwanese Journal of Obstetrics and Gynecology 2012; 51 (2): 206–211. doi: 10.1016/j.tjog.2012.04.007

15. Danisman N, Kahyaoglu S, Celen S, Kahyaoglou I, Candemir Z et al. A retrospective analysis of amniocenteses performed for advanced maternal age and various other indications in Turkish women. Journal of Maternal Fetal and Neonatal Medicine 2013; 26 (3): 242–245. doi: 10.3109/14767058.2012.733756

16. Han SH, An JW, Jeong GY, Yoon HR, Lee A et al. Clinical and cytogenetic findings on 31615 mid-trimester amniocenteses. Korean Journal of Laboratory Medicine 2008; 28 (5): 378–385. doi: 10.3343/kjlm.2008.28.5.378

17. Andrew C, Koshy T, Gopal S, Paul SFD. A retrospective exploratory study of fetal genetic invasive procedures at a University Hospital. Journal of Obstetrics and Gynaecology 2018; 38 (7): 906–910. doi: 10.1080/01443615.2018.1433645

18. Demirhan O, Pazarbaş A, Güzel Al, Taştemir D, Yilmaz B et al. The reliability of maternal serum triple test in prenatal diagnosis of fetal chromosomal abnormalities of pregnant Turkish women. Genetic Testing and Molecular Biomarkers 2011; 15 (10): 701–707. doi: 10.1089/gtm.2010.0171

19. Hsieh FJ, Ko TM, Tseng LH, Chang LS, Pan MF et al. Prenatal cytogenetic diagnosis in amniocentesis. Journal of the Formosan Medical Association 1992; 91 (3): 276–282.

20. Kagan KO, Chitty LS, Cicero S, Eleftheriades M, Nicolaides KH. Ultrasound findings before amniocentesis in selecting the method of analysing the sample. Prenatal Diagnosis 2007; 27 (1): 34–39. doi: 10.1002/pd.1615

21. Karaoguz MY, Bal F, Yakut T, Ercelean NO, Ergun MA et al. Cytogenetic results of amniocentesis materials: incidence of abnormal karyotypes in the Turkish collaborative study. Genetic Counseling 2006; 17 (2): 219–230.

22. Sun Y, Zhang P, Zhang N, Rong L, Yu X et al. Cytogenetic analysis of 3387 umbilical cord blood in pregnant women at high risk for chromosomal abnormalities. Molecular Cytogenetics 2020; 13: 2. doi: 10.1186/s13039-020-0469-6

23. Jummaat F, Ahmad S, Mohamed Ismail NA. 5-year review on amniocentesis and its maternal fetal complications. Hormone Molecular Biology and Clinical Investigation 2019; 40 (2). doi: 10.1515/hmbci-2019-0006

24. Ocak Z, Özli T, Yavuzoğlu HF, Özyurt O, Aygün M. Clinical and cytogenetic results of a large series of amniocenteses cases from Turkey: report of 6124 cases. Journal of Obstetrics and Gynaecology Research 2014; 40 (1): 139–146. doi: 10.1111/jog.12144

25. Tekcan A, Tural S, Elbistan M, Kara N, Guven D et al. The combined QF-PCR and cytogenetic approach in prenatal diagnosis. Molecular Biology Reports 2014; 41 (11): 7431–7436. doi: 10.1007/s11033-014-3630-7